We are live on
!
Find out more
AR
Advisory Research Portfolio holdings
AUM
$813M
1-Year Est. Return
36.71%
This Fund
S&P 500
This Quarter
Est. Return
+0.62%
1 Year Est. Return
+36.71%
3 Year Est. Return
+123.04%
5 Year Est. Return
+262.63%
10 Year Est. Return
+840.35%
AUM
$720M
AUM Growth
-$59.6M
(-7.6%)
Cap. Flow
-$36.5M
Cap. Flow
% of AUM
-5.06%
Top 10 Holdings %
Top 10 Hldgs %
17.21%
Holding
510
New
74
Increased
122
Reduced
203
Closed
86
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
GSK
GSK
|
+$4.08M |
| 2 |
JBTM
JBT Marel
JBTM
|
+$3.91M |
| 3 |
PRSU
Pursuit Attractions and Hospitality Inc
PRSU
|
+$3.66M |
| 4 |
Northern Oil and Gas
NOG
|
+$3.45M |
| 5 |
Devon Energy
DVN
|
+$3.09M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
DEN
Denbury Inc.
DEN
|
+$7.07M |
| 2 |
Reliance Steel & Aluminium
RS
|
+$5.93M |
| 3 |
CHX
ChampionX
CHX
|
+$4.74M |
| 4 |
Accenture
ACN
|
+$4.11M |
| 5 |
On Holding
ONON
|
+$3.96M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 21.49% |
| 2 | Consumer Discretionary | 17.64% |
| 3 | Industrials | 15.79% |
| 4 | Healthcare | 11.67% |
| 5 | Financials | 10.37% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
126
Cellebrite
CLBT
$3.54B
| $1.69M | 0.23% |
220,335
+150,931
| +217% | +$1.13M |
|
127
Holley
HLLY
$314M
| $1.68M | 0.23% |
336,561
+15,772
| +5% | +$89.3K |
|
128
iShares 5-10 Year Investment Grade Corporate Bond ETF
IGIB
$18.3B
| $1.63M | 0.23% |
33,566
| – | – |
|
129
Preformed Line Products
PLPC
$1.52B
| $1.62M | 0.22% |
9,943
+1,427
| +17% | +$238K |
|
130
Invesco S&P 500 Equal Weight ETF
RSP
$96.1B
| $1.61M | 0.22% |
11,395
+2
| +0% | +$299 |
|
|
CBAY
131
DELISTED
Cymabay Therapeutics
CBAY
| $1.56M | 0.22% |
104,540
-17,693
| -14% | -$235K |
|
132
iShares MBS ETF
MBB
$39B
| $1.56M | 0.22% |
17,518
| – | – |
|
133
First Merchants
FRME
$2.72B
| $1.55M | 0.21% |
55,640
-195
| -0.3% | -$5.84K |
|
134
C3.ai
AI
$1.27B
| $1.53M | 0.21% |
60,106
+10,446
| +21% | +$349K |
|
135
Ares Capital
ARCC
$13.5B
| $1.53M | 0.21% |
78,377
-1,231
| -2% | -$23.9K |
|
136
Noble Corp
NE
$6.9B
| $1.52M | 0.21% |
30,079
+11,990
| +66% | +$611K |
|
137
Trinity Industries
TRN
$2.97B
| $1.52M | 0.21% |
62,437
-2,110
| -3% | -$53.2K |
|
138
Oracle
ORCL
$331B
| $1.52M | 0.21% |
14,330
-135
| -0.9% | -$15.6K |
|
139
LegalZoom.com
LZ
$1.23B
| $1.52M | 0.21% |
138,628
-156,280
| -53% | -$1.92M |
|
140
Tesla
TSLA
$1.24T
| $1.5M | 0.21% |
6,005
-2,316
| -28% | -$595K |
|
141
McDonald's
MCD
$188B
| $1.48M | 0.2% |
5,600
-66
| -1% | -$18.8K |
|
142
Union Pacific
UNP
$183B
| $1.44M | 0.2% |
7,090
-231
| -3% | -$50.3K |
|
143
Bank of America
BAC
$435B
| $1.43M | 0.2% |
52,335
-2,343
| -4% | -$69.3K |
|
144
Kirby Corp
KEX
$7.95B
| $1.41M | 0.2% |
+16,990
| New | +$1.37M |
|
145
Abbott
ABT
$180B
| $1.4M | 0.19% |
14,425
+821
| +6% | +$86.2K |
|
|
EXAS
146
DELISTED
Exact Sciences
EXAS
| $1.39M | 0.19% |
20,311
-5,742
| -22% | -$487K |
|
147
Regal Rexnord
RRX
$14.2B
| $1.38M | 0.19% |
9,644
+1,071
| +12% | +$165K |
|
148
Evolent Health
EVH
$475M
| $1.37M | 0.19% |
50,354
-13,517
| -21% | -$376K |
|
|
ROVR
149
DELISTED
Rover Group, Inc. Class A Common Stock
ROVR
| $1.37M | 0.19% |
218,674
-77,419
| -26% | -$462K |
|
150
Vermilion Energy
VET
$1.73B
| $1.37M | 0.19% |
93,525
-10,333
| -10% | -$145K |
|
Similar funds
VFG
SLG
KCP
UAG
PS
CICI
RPAM
BBI
Advisory Research's Q3 2023 Portfolio in Review
As of Q3 2023, Advisory Research held 510 positions worth $720M, down 7.6% from $780M the previous quarter. Its ten largest holdings account for 17% of the portfolio.
Advisory Research withdrew a net $36.5M in Q3 2023, closing 86 positions and reducing 203 holdings. Its most notable exit was Livent Corporation, an estimated $2.81M position sold in full.
By sector, the portfolio is most concentrated in Technology at 21% of assets, down from 22% a quarter earlier, followed by Consumer Discretionary and Industrials.
Against the trend, Advisory Research opened a new position in JBT Marel worth $3.67M.
- Advisory Research's largest Q3 2023 buy was JBT Marel: 34,900 shares worth $3.67M.
- Advisory Research added most to GSK in Q3 2023, an estimated $4.08M increase.
- Advisory Research's biggest Q3 2023 reduction was Denbury Inc., cutting an estimated $7.07M.
- Advisory Research fully exited Livent Corporation in Q3 2023, selling an estimated $2.81M.
- Advisory Research's ten largest holdings make up 17% of its $720M portfolio in Q3 2023.
- Advisory Research opened 74 new positions and closed 86 in Q3 2023.
- Advisory Research's portfolio value fell 7.6% quarter-over-quarter to $720M.
Based on Advisory Research's 13F filing for Q3 2023, filed 13 Nov 2023.